tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Baxter International (BAX) and Dexcom (DXCM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNYResearch Report), Baxter International (BAXResearch Report) and Dexcom (DXCMResearch Report).

Alnylam Pharma (ALNY)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Alnylam Pharma, with a price target of $159.00. The company’s shares closed last Thursday at $143.52.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.3% and a 51.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Vertex Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $196.74, a 43.6% upside from current levels. In a report issued on July 18, SVB Securities also maintained a Hold rating on the stock with a $97.00 price target.

See today’s best-performing stocks on TipRanks >>

Baxter International (BAX)

Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Baxter International today and set a price target of $72.00. The company’s shares closed last Thursday at $59.50, close to its 52-week low of $58.91.

According to TipRanks.com, Ranieri is a 1-star analyst with an average return of -5.6% and a 46.4% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Integra Lifesciences, and Intuitive Surgical.

Currently, the analyst consensus on Baxter International is a Strong Buy with an average price target of $73.40, which is a 18.9% upside from current levels. In a report issued on July 18, Stifel Nicolaus also maintained a Buy rating on the stock with a $75.00 price target.

Dexcom (DXCM)

In a report released today, Cecilia Furlong from Morgan Stanley maintained a Hold rating on Dexcom, with a price target of $83.00. The company’s shares closed last Thursday at $86.99.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 20.3% and a 52.2% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $101.38 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More